[1] Fontana R J, Liou I, Reuben A, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury[J]. Hepatology, 2023, 77(3):1036-1065. [2] 刘成海.中草药相关肝损伤的研究进展与挑战[J].临床肝胆病杂志,2024,40(8):1505-1511. [3] Shen T, Liu Y, Shang J, et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156(8):2230-2241. [4] Suk K T, Kim D J, Kim C H, et al. A prospective nationwide study of drug-induced liver injury in Korea[J]. AM J Gastroenterol, 2012, 107(9):1380-1387. [5] Bessone F, García-Cortés M, Medina-Caliz I, et al. Herbal and dietary supplements-induced liver injury in Latin America:experience from the LATINDILI network[J]. Clin Gastroenterol Hepatol, 2022,20(3):e548-e563. [6] 中国医药生物技术协会药物性肝损伤防治技术专业委员会,中华医学会肝病学分会药物性肝病学组.中国药物性肝损伤诊治指南(2023年版)[J].中华肝脏病杂志,2023,31(4):355-384. [7] Hayashi P H, Lucena M I, Fontana R J, et al. A revised electronic version of RUCAM for the diagnosis of DILI[J]. Hepatology, 2022, 76(1):18-31. [8] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2024年版)[J].中华肝脏病杂志,2025,33(1):18-33. [9] Johnson P J, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma:a new evidence-based approach-the ALBI grade[J]. J Clin Oncol, 2014, 33(6):550-558. [10] Chen Q, Zhong R, Wang Y, et al. The albumin-bilirubin score as a predictor of liver-related mortality in primary biliary cholangitis with compensated cirrhosis[J]. Dig Dis, 2023, 41(6):946-956. [11] Fujita K, Nomura T, Morishita A, et al. Prediction of transplant-free survival through albumin-bilirubin score in primary biliary cholangitis[J]. J Clin Med, 2019, 8(8):508-518. [12] Peng Y, Wei Q, He Y, et al. ALBI versus Child-Pugh in predicting outcome of patients with HCC:a systematic review[J]. Expert Rev Gastroenterol Hepatol, 2020, 14(5):383-400. [13] Toyoda H, Johnson P J. The ALBI score:from liver function in patients with HCC to a general measure of liver function[J]. JHEP Rep, 2022, 4(10):100557. |